HSCS.NASDAQHeartsciences INC
DEF: HeartSciences Sets 2026 Annual Meeting Agenda, Boosts Equity Plan
Sentiment:
Proxy Statement
HeartSciences Inc. announces its 2026 Annual Meeting of Shareholders to address director election, an expanded equity incentive plan, officer liability exculpation, and auditor ratification.
Capital raiseThe Company entered into a $1M Loan and Security Agreement in April 2020 with Front Range Ventures, LLC and John Q. Adams, which has seen multiple maturity extensions, most recently to September 30, 2026.In October 2023, the Company issued warrants to FRV and Mr. Adams as consideration for an interest maturity extension.On November 16, 2023, the Company converted $585,006 of principal and interest from the JQA Note into 36,563 shares of Common Stock and amended warrants for Mr. Adams.Pursuant to a Securities Purchase Agreement with Mount Sinai, on November 16, 2023, the Company issued 48,549 shares of Common Stock, pre-funded warrants for 7,107 shares, and common stock warrants for 9,142 shares to Mount Sinai in exchange for licensing agreements.
Summary
- The Annual Meeting of Shareholders will be held virtually on Thursday, April 30, 2026, at 10:00 a.m. Eastern Time.
- Shareholders will vote on the election of Andrew Simpson as a Class III Director.
- A proposal seeks to increase the shares reserved for the 2023 Equity Incentive Plan to 1,250,000 shares plus Evergreen Shares, up from the current 85,000 plus Evergreen Shares (which was previously amended to 1,000,000 plus Evergreen Shares on July 9, 2025).
- Shareholders will consider an amendment to the Company's Certificate of Formation to exculpate officers from personal liability under certain circumstances, as permitted by Texas law.
- The appointment of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2026, is up for ratification.
- A proposal to approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies will also be voted upon.
- The record date for shareholders entitled to vote at the Annual Meeting is March 6, 2026.
- As of the record date, there were 3,184,700 shares of common stock and 292,998 shares of common stock issuable upon conversion of 380,440 Series C Preferred Stock outstanding and entitled to vote.
- The Company paid approximately $305,000 in accrued interest to Front Range Ventures, LLC (FRV) during the fiscal year ended April 30, 2025, and an additional $61,000 in October 2025 related to a $1M loan.
- Executive and non-employee director compensation for fiscal year 2025 included cash fees and significant option/restricted stock unit awards, with vesting often tied to FDA clearances or achieving $250,000+ in quarterly revenue.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this proxy statement as moderately positive, reflecting standard corporate governance actions and strategic moves like the Mount Sinai licensing deal. While the equity plan increase and officer exculpation have potential downsides, they are presented as necessary for growth and talent management, and the company's focus on FDA clearances and revenue targets indicates a clear path forward.
Positives
- The Company is actively pursuing FDA clearances for its MyoVista Device (including AI algorithm) and MyoVista Insights Cloud Platform (with first AI algorithm), which are key milestones for executive compensation vesting.
- The licensing agreements with Mount Sinai for 13 AI cardiovascular algorithms, 2 data science methods, and 3 filed patents represent significant strategic intellectual property acquisition.
- The Board of Directors maintains strong corporate governance practices, including a Code of Ethics, insider trading guidelines, regular self-assessments, and independent committee members.
- The Company is undertaking a formal review of Board of Directors compensation, potentially including retaining an expert consulting firm, to ensure competitive and appropriate remuneration.
Negatives
- The proposal to exculpate officers from personal liability, while permitted by Texas law and intended to aid recruitment/retention, could be perceived as reducing accountability for officers under certain circumstances.
- The increase in the equity incentive plan shares could lead to further dilution for existing shareholders, although it is presented as necessary for attracting and retaining talent.
- The Company has repeatedly extended the maturity date of the $1M loan with Front Range Ventures, LLC, with the latest extension to September 30, 2026, indicating ongoing debt management.
Risks
- Failure to approve the increase in shares for the 2023 Equity Incentive Plan could hinder the Company's ability to attract and retain key employees, executive officers, directors, and consultants.
- If the proposal for officer exculpation is not approved, the Company may face challenges in recruiting and retaining skilled officers due to potential personal liability risks and increased litigation costs.
- The Company's ability to achieve certain executive compensation vesting conditions (e.g., FDA clearances, $250,000+ quarterly revenue) is subject to operational and regulatory risks.
- The $1M Loan and Security Agreement with Front Range Ventures, LLC, involves a significant related-party debt that has required multiple maturity extensions, indicating potential liquidity or repayment challenges.
Future Outlook
The Company's future outlook is tied to achieving FDA clearances for its MyoVista Device (including AI algorithm) and MyoVista Insights Cloud Platform (with first AI algorithm), which are critical milestones for executive compensation vesting. Additionally, achieving quarterly revenue of $250,000 or more after November 28, 2025, is a key performance indicator for accelerated vesting of certain restricted stock units for management and directors. The proposed increase in the equity incentive plan aims to support future talent attraction and retention.
Management Comments
- The Board of Directors believes it is in the best interests of the Company and its shareholders to amend the 2023 Equity Incentive Plan to continue providing appropriate levels and types of equity compensation for employees, executive officers, directors, and consultants.
- The Board believes it is appropriate to provide protection to the Company's officers to the fullest extent permitted by the Texas Business Organizations Code, as the nature of the officer role often requires difficult decisions on crucial matters.
- The Board expects other peer companies to adopt exculpation clauses for officers, and failing to adopt the proposed amendment could impact recruitment and retention of officers.
- The Board believes that the limited scope of officer exculpation strikes an appropriate balance between shareholders' interest in accountability and the benefits of enhanced recruitment and reduced litigation costs.
Industry Context
StockSavvy.ai notes that HeartSciences Inc. operates in the medical technology sector, specifically focusing on AI cardiovascular algorithms. The strategic licensing agreements with Mount Sinai for AI algorithms and data science methods position the Company to leverage advancements in artificial intelligence for cardiovascular diagnostics. The emphasis on FDA clearances for its MyoVista device and cloud platform indicates a focus on regulatory approval and commercialization in a highly regulated industry. The competitive landscape for medical device and AI diagnostics companies often involves significant R&D investment, regulatory hurdles, and the need to attract and retain specialized talent, which the expanded equity incentive plan aims to address.
Comparison to Industry Standards
- The proposed officer exculpation amendment aligns with a recent trend in corporate governance, particularly following legislative changes in states like Texas, to extend liability protections to officers, similar to those already afforded to directors. This is a response to increasing litigation against corporate officers.
- The expansion of the equity incentive plan is a common practice among growth-oriented technology and medical device companies to incentivize and retain key talent in a competitive market. While specific comparable company data is not provided, such plans are standard tools for compensation in the industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Proposed Amendment to Certificate of Formation | To provide for exculpation of officers from personal liability under certain circumstances as allowed by Texas law, specifically Senate Bill 2411, effective September 1, 2025. This limits liability for monetary damages for acts or omissions in an officer's capacity, with exceptions for breaches of duty of loyalty, bad faith, intentional misconduct, knowing violation of law, or improper personal benefit. | Upon filing with the Secretary of State of Texas, if approved by shareholders. | Aims to reduce litigation risk, control insurance costs, and enhance the Company's ability to recruit and retain skilled officers. May be perceived by some shareholders as reducing officer accountability. |
| Increase in Equity Incentive Plan Shares | Proposal to increase the maximum aggregate number of shares reserved for issuance under the 2023 Equity Incentive Plan to 1,250,000 shares plus Evergreen Shares. This follows previous amendments from 85,000 to 1,000,000 and then to 1,250,000 shares plus Evergreen Shares. | Upon shareholder approval. | Intended to provide sufficient equity compensation to attract, retain, and incentivize employees, executive officers, directors, and consultants, aligning their interests with shareholder value creation. May result in dilution for existing shareholders. |
Related Party Transactions
- The Company has a $1M Loan and Security Agreement from April 2020 with Front Range Ventures, LLC (FRV) and John Q. Adams (a former director and shareholder). The FRV Note's maturity has been extended multiple times, most recently to September 30, 2026. The Company paid approximately $305,000 in accrued interest to FRV in fiscal year 2025 and $61,000 in October 2025.
- In October 2023, the Company issued warrants to FRV and Mr. Adams as consideration for an interest maturity extension.
- On November 16, 2023, the Company converted $585,006 of principal and interest from the JQA Note into 36,563 shares of Common Stock and amended warrants for Mr. Adams.
- The Company entered into License Agreements with Mount Sinai on September 20, 2023, to commercialize AI cardiovascular algorithms. In connection, the Company issued 48,549 common shares, pre-funded warrants for 7,107 shares, and common stock warrants for 9,142 shares to Mount Sinai on November 16, 2023.
- Front Range Ventures, LLC, has the right to designate a director to the Company's Board, which has not been exercised as of the 2025 Annual Report.
Stakeholder Impact
- Shareholders: Potential dilution from the expanded equity incentive plan, but also potential benefit from enhanced ability to attract and retain talent. The officer exculpation proposal balances officer protection with shareholder accountability.
- Officers and Directors: Direct benefit from increased equity compensation opportunities and reduced personal liability under the proposed exculpation amendment, which aims to improve recruitment and retention.
- Employees: Benefit from the expanded equity incentive plan, providing more opportunities for stock options and restricted stock units as part of their compensation.
- Creditors (Front Range Ventures, LLC): The repeated extensions of the loan maturity date indicate ongoing engagement and management of the debt relationship.
Next Steps
- Shareholders to vote on proposals at the Annual Meeting on April 30, 2026.
- Company management to continue efforts towards achieving FDA clearance for MyoVista Device (including AI algorithm) and MyoVista Insights Cloud Platform (with first AI algorithm).
- Company to work towards achieving $250,000 or more in revenue in any fiscal quarter ending after November 28, 2025, to trigger RSU vesting.
- If approved, the Certificate of Amendment for officer exculpation will be filed with the Secretary of State of Texas promptly after shareholder approval.
- The Audit Committee will reconsider the retention of Haskell & White LLP if shareholders fail to ratify their appointment.
Key Dates
| Date | Description |
|---|---|
| 2007-08-16 | Date of formation of HeartSciences Inc. |
| 2012-07-01 | Andrew Simpson joined the Company as a director. |
| 2013-06-01 | Andrew Simpson became Chairman of the Board; Mark Hilz became a director and CEO. |
| 2014-01-01 | Brian Szymczak joined the Company as a director. |
| 2016-05-01 | Grant date for certain stock options to Andrew Simpson and Mark Hilz. |
| 2019-09-01 | Grant date for certain stock options to Andrew Simpson and Mark Hilz. |
| 2020-04-01 | Company entered into $1M Loan and Security Agreement with Front Range Ventures, LLC and John Q. Adams. |
| 2020-05-01 | Bruce Bent joined the Company as a director. |
| 2020-11-06 | Grant date for certain stock options to Andrew Simpson and Mark Hilz. |
| 2021-10-15 | Employment agreement entered with Danielle Watson, effective November 4, 2021. |
| 2022-02-01 | Grant date for certain stock options to Danielle Watson. |
| 2022-03-01 | Grant date for certain stock options to Andrew Simpson, Mark Hilz, and Danielle Watson. |
| 2022-03-01 | Andrew Simpson became President and CEO; Mark Hilz became COO and Secretary. |
| 2022-04-05 | Employment agreements entered with Andrew Simpson and Mark Hilz. |
| 2022-04-01 | Danielle Watson appointed Chief Financial Officer. |
| 2022-10-01 | David R. Wells founded Atlas Bookkeeping, LLC. |
| 2022-12-01 | David R. Wells joined the Company as a director. |
| 2023-01-01 | Amendment to $1M Loan and Security Agreement extending FRV Note maturity to September 30, 2024, and JQA Note interest due September 30, 2023, principal/interest due March 31, 2024. |
| 2023-01-17 | Shareholders approved the 2023 Equity Incentive Plan at the annual meeting. |
| 2023-03-15 | Board of Directors adopted the 2023 Equity Incentive Plan. |
| 2023-03-20 | Grant date for certain stock options to Andrew Simpson, Mark Hilz, and Danielle Watson. |
| 2023-08-01 | David R. Wells became Chief Financial Officer of Envoy Medical, Inc. |
| 2023-09-20 | Company entered into License Agreements with Mount Sinai and Securities Purchase Agreement. |
| 2023-10-01 | Company issued $1M Lender Warrants to FRV and Mr. Adams for interest maturity extension. |
| 2023-11-16 | Company entered into note conversion letter agreement with John Q. Adams, issuing 36,563 common shares and amending warrants. |
| 2023-11-16 | Company issued 48,549 common shares, pre-funded warrants for 7,107 shares, and common stock warrants for 9,142 shares to Mount Sinai. |
| 2023-11-27 | Amendment No. 1 to the 2023 Equity Incentive Plan executed, increasing shares to 8,500,000 plus Evergreen Shares. |
| 2023-11-28 | Date after which achieving $250,000 or more of revenue in any fiscal quarter triggers accelerated RSU vesting. |
| 2023-12-01 | All material closing conditions of the Mount Sinai Securities Purchase Agreement satisfied, making MTS Warrants fully exercisable. |
| 2024-03-05 | Company filed Registration Statement on Form S-1 for resale of MTS Securities. |
| 2024-03-13 | Registration Statement on Form S-1 for resale of MTS Securities declared effective. |
| 2024-05-01 | Start of fiscal year for which the 2023 Equity Incentive Plan's Evergreen Shares mechanism begins automatic increase. |
| 2024-05-17 | Corporation effected a 1-for-100 reverse stock split. |
| 2024-07-24 | 2025 Annual Report on Form 10-K filed with the SEC. |
| 2024-08-19 | Amendment No. 6 to Loan and Security Agreement with FRV, extending maturity to September 30, 2025. |
| 2024-09-30 | Accrued interest payment due to FRV under Amendment No. 6. |
| 2025-01-16 | Grant date for certain stock options to Andrew Simpson, Mark Hilz, and Danielle Watson. |
| 2025-04-30 | End of fiscal year 2025. |
| 2025-07-08 | Compensation Committee granted options to Andrew Simpson (275,000), Mark Hilz (225,000), and Danielle Watson (25,000). |
| 2025-07-09 | Board of Directors approved Amendment No. 2 to the 2023 Equity Incentive Plan, increasing shares to 1,000,000 plus Evergreen Shares. |
| 2025-07-09 | Compensation Committee approved award of 25,000 stock options to each non-employee director (Szymczak, Bent, Wells) at $4.37 exercise price. |
| 2025-07-09 | 68,750 RSUs granted to Andrew Simpson, vesting immediately upon FDA clearance or Change of Control. |
| 2025-07-09 | 56,250 RSUs granted to Mark Hilz, vesting immediately upon FDA clearance or Change of Control. |
| 2025-09-01 | Effective date of Texas Senate Bill 2411, permitting officer exculpation. |
| 2025-09-26 | Amendment No. 7 of Loan and Security Agreement with FRV, extending maturity to September 30, 2026. |
| 2025-09-30 | Accrued interest payment due to FRV under Amendment No. 7. |
| 2025-10-09 | One-fourth of Director Options granted on July 9, 2025, vested. |
| 2025-10-01 | Company paid approximately $61,000 in accrued interest to FRV. |
| 2025-11-25 | Compensation Committee approved 70,000 shares of restricted common stock for Andrew Simpson and 45,000 RSUs for Mark Hilz. |
| 2025-12-03 | Board of Directors approved Amendment No. 3 to the 2023 Equity Incentive Plan, further increasing shares to 1,250,000 plus Evergreen Shares. |
| 2025-12-03 | Board of Directors approved award of 15,000 RSUs to each non-employee director (Szymczak, Bent, Wells) and Danielle Watson. |
| 2026-03-06 | Record date for shareholders entitled to notice of and to vote at the Annual Meeting. |
| 2026-03-17 | Proxy Statement made available to shareholders. |
| 2026-03-19 | Notice of Internet Availability of Proxy Materials intended to be mailed to shareholders. |
| 2026-04-16 | Deadline for beneficial owners to register in advance to attend the Annual Meeting online by webcast. |
| 2026-04-30 | Date of the Annual Meeting of Shareholders. |
| 2026-05-01 | Start of fiscal year for which the 2023 Equity Incentive Plan's Evergreen Shares mechanism will automatically increase shares. |
| 2026-05-01 | Expiration date for certain stock options granted on May 1, 2016, to Andrew Simpson and Mark Hilz. |
| 2026-09-01 | Expiration date for certain stock options granted on September 1, 2019, to Andrew Simpson and Mark Hilz. |
| 2026-09-30 | Extended maturity date for the FRV Note under Amendment No. 7. |
| 2026-11-06 | Expiration date for certain stock options granted on November 6, 2020, to Andrew Simpson and Mark Hilz. |
| 2026-12-31 | Deadline for shareholder proposals for the 2026 Annual Meeting to be considered for inclusion in proxy materials. |
| 2027-01-30 | Earliest date for shareholder notice of director nominations for the 2026 Annual Meeting (90 days prior to April 30, 2027). |
| 2027-04-01 | Latest date for shareholder notice of director nominations for the 2026 Annual Meeting (120 days prior to April 30, 2027). |
| 2027-04-30 | Expected date of the 2027 Annual Meeting of Shareholders. |
| 2029-09-01 | Expiration date for certain stock options granted on September 1, 2019, to Andrew Simpson and Mark Hilz. |
| 2030-11-06 | Expiration date for certain stock options granted on November 6, 2020, to Andrew Simpson and Mark Hilz. |
| 2032-02-01 | Expiration date for certain stock options granted on February 1, 2022, to Danielle Watson. |
| 2032-03-01 | Expiration date for certain stock options granted on March 1, 2022, to Andrew Simpson, Mark Hilz, and Danielle Watson. |
| 2033-03-20 | Expiration date for certain stock options granted on March 20, 2023, to Andrew Simpson, Mark Hilz, and Danielle Watson. |
| 2035-01-16 | Expiration date for certain stock options granted on January 16, 2025, to Andrew Simpson, Mark Hilz, and Danielle Watson. |
Recommendation
holdThis filing is a routine proxy statement for an annual meeting, outlining proposals related to corporate governance, executive compensation, and auditor ratification. While the Mount Sinai licensing deal is a positive strategic development, it was previously announced. The proposals themselves, such as increasing the equity incentive plan and officer exculpation, are common corporate actions that do not fundamentally alter the company's immediate financial outlook or operational trajectory. Therefore, a 'hold' recommendation is appropriate as the filing provides important context for governance and future incentives but does not present new information warranting a change in investment stance.
Keywords
Proxy Statement, Annual Meeting, Equity Incentive Plan, Officer Exculpation, Corporate Governance, Director Election, Auditor Ratification, HeartSciences Inc., SEC Filing, Shareholder Vote, Medical Technology, AI Cardiovascular Algorithms, FDA Clearance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.